ArticleJournal of molecular histology2026
Ultrasound-targeted delivery of miR-513a-5p inhibits ferroptosis and restores vascular function in preeclampsia.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is a hypertensive pregnancy disorder with limited therapeutic options. This study explores the role of miR-513a-5p in modulating ferroptosis via TXNIP and evaluates its therapeutic delivery using ultrasound-targeted microbubble destruction (UTMD). miR-513a-5p was identified as significantly downregulated in PE through GEO analysis (GSE84260). To assess its function, miR-513a-5p was overexpressed in HTR-8/SVneo and TEV-1 trophoblast cells, and its effects on proliferation, apoptosis, migration, and ferroptosis were evaluated. TXNIP was investigated as a mechanistic target using dual-luciferase and RNA pulldown assays, and its functional relevance was tested via rescue experiments. To assess translational applicability, miR-513a-5p was delivered using UTMD both in vitro and via tail vein injection in a rat model of PE. On gestational day (GD) 19, blood pressure, urinary protein, and fetal survival were assessed. On GD22, oxidative stress markers such as reactive oxygen species (ROS), malondialdehyde (MDA), Fe2+, glutathione (GSH), superoxide dismutase (SOD), ferroptosis regulators (GPX4, SLC7A11), and angiogenic factors (sFlt-1, PlGF, VEGF) were measured. Bioinformatics analysis revealed miR-513a-5p as one of the significantly downregulated miRNAs in PE which was validated in placental tissues. miR-513a-5p overexpression promoted trophoblast proliferation, migration, and EMT, and reduced apoptosis and ferroptosis in trophoblast cells. TXNIP was validated as a direct target of miR-513a-5p, and its reintroduction reversed the protective effects of miR-513a-5p. UTMD enhanced miR-513a-5p delivery in vitro compared to lipofection and improved trophoblast viability and function. In vivo, administration of UTMD-mediated miR-513a-5p delivery reduced blood pressure, proteinuria, and oxidative stress, and improved fetal survival, antioxidant levels, and vascular markers. UTMD enhanced miR-513a-5p delivery in vitro and promoted trophoblast function.
Indexed as
Identifiers
41787200What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.